Brown Brothers Harriman & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.75K | Hold |
23
| – | – | ﹤0.01% | 1496 |
|
|
2026
Q1 | $6.41K | Hold |
23
| – | – | ﹤0.01% | 1439 |
|
|
2025
Q4 | $6.97K | Sell |
23
-19
| -45% | -$5.93K | ﹤0.01% | 1426 |
|
|
2025
Q3 | $11.8K | Hold |
42
| – | – | ﹤0.01% | 1262 |
|
|
2025
Q2 | $10.1K | Sell |
42
-92
| -69% | -$21.7K | ﹤0.01% | 1194 |
|
|
2025
Q1 | $32.6K | Sell |
134
-78
| -37% | -$23.5K | ﹤0.01% | 891 |
|
|
2024
Q4 | $69.6K | Buy |
212
+205
| +2,929% | +$69.6K | ﹤0.01% | 811 |
|
|
2024
Q3 | $2.34K | Buy |
+7
| New | +$2.22K | ﹤0.01% | 1282 |
|
|
2024
Q2 | – | Sell |
-45
| Closed | -$15.6K | – | 1160 |
|
|
2024
Q1 | $15.6K | Hold |
45
| – | – | ﹤0.01% | 937 |
|
|
2023
Q4 | $14.5K | Sell |
45
-118
| -72% | -$37K | ﹤0.01% | 897 |
|
|
2023
Q3 | $58.4K | Hold |
163
| – | – | ﹤0.01% | 685 |
|
|
2023
Q2 | $61.8K | Sell |
163
-1
| -0.6% | -$407 | ﹤0.01% | 678 |
|
|
2023
Q1 | $78.6K | Buy |
164
+1
| +0.6% | +$468 | ﹤0.01% | 665 |
|
|
2022
Q4 | $68.5K | Hold |
163
| – | – | ﹤0.01% | 663 |
|
|
2022
Q3 | $68K | Hold |
163
| – | – | ﹤0.01% | 674 |
|
|
2022
Q2 | $81K | Hold |
163
| – | – | ﹤0.01% | 614 |
|
|
2022
Q1 | $92K | Buy |
163
+45
| +38% | +$27.1K | ﹤0.01% | 649 |
|
|
2021
Q4 | $89K | Hold |
118
| – | – | ﹤0.01% | 607 |
|
|
2021
Q3 | $88K | Hold |
118
| – | – | ﹤0.01% | 585 |
|
|
2021
Q2 | $76K | Hold |
118
| – | – | ﹤0.01% | 601 |
|
|
2021
Q1 | $67K | Hold |
118
| – | – | ﹤0.01% | 594 |
|
|
2020
Q4 | $69K | Buy |
118
+7
| +6% | +$3.99K | ﹤0.01% | 615 |
|
|
2020
Q3 | $57K | Hold |
111
| – | – | ﹤0.01% | 555 |
|
|
2020
Q2 | $50K | Hold |
111
| – | – | ﹤0.01% | 576 |
|
|
2020
Q1 | $39K | Hold |
111
| – | – | ﹤0.01% | 557 |
|
|
2019
Q4 | $41K | Hold |
111
| – | – | ﹤0.01% | 699 |
|
|
2019
Q3 | $37K | Sell |
111
-25
| -18% | -$8.15K | ﹤0.01% | 697 |
|
|
2019
Q2 | $43K | Hold |
136
| – | – | ﹤0.01% | 608 |
|
|
2019
Q1 | $42K | Hold |
136
| – | – | ﹤0.01% | 608 |
|
|
2018
Q4 | $32K | Hold |
136
| – | – | ﹤0.01% | 559 |
|
|
2018
Q3 | $43K | Buy |
136
+25
| +23% | +$7.76K | ﹤0.01% | 535 |
|
|
2018
Q2 | $32K | Hold |
111
| – | – | ﹤0.01% | 545 |
|
|
2018
Q1 | $28K | Hold |
111
| – | – | ﹤0.01% | 540 |
|
|
2017
Q4 | $26K | Hold |
111
| – | – | ﹤0.01% | 606 |
|
|
2017
Q3 | $25K | Hold |
111
| – | – | ﹤0.01% | 561 |
|
|
2017
Q2 | $25K | Hold |
111
| – | – | ﹤0.01% | 566 |
|
|
2017
Q1 | $22K | Hold |
111
| – | – | ﹤0.01% | 580 |
|
|
2016
Q4 | $20K | Hold |
111
| – | – | ﹤0.01% | 622 |
|
|
2016
Q3 | $18K | Hold |
111
| – | – | ﹤0.01% | 560 |
|
|
2016
Q2 | $16K | Buy |
+111
| New | +$15.8K | ﹤0.01% | 580 |
|
|
2015
Q4 | – | Sell |
-9
| Closed | -$1K | – | 746 |
|
|
2015
Q3 | $1K | Buy |
+9
| New | +$1.29K | ﹤0.01% | 801 |
|
|
2015
Q1 | – | Sell |
-18
| Closed | -$2K | – | 768 |
|
|
2014
Q4 | $2K | Buy |
+18
| New | +$2.07K | ﹤0.01% | 814 |
|
|
2013
Q4 | – | Sell |
-45
| Closed | -$5K | – | 652 |
|
|
2013
Q3 | $5K | Sell |
45
-615,339
| -100% | -$72.6M | ﹤0.01% | 616 |
|
|
2013
Q2 | $69M | Buy |
+615,384
| New | +$72.2M | 0.33% | 34 |
|
Other funds holding BIO
AI
Brown Brothers Harriman & Co's BIO Position: Q2 2026 in Review
Brown Brothers Harriman & Co held its Bio-Rad Laboratories Class A (BIO) position steady in Q2 2026 at 23 shares worth $6.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1496.
Brown Brothers Harriman & Co first reported a position in BIO in Q2 2013 and has held it in 44 quarters since. The position peaked at $69M in Q2 2013. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Brown Brothers Harriman & Co held 23 shares of Bio-Rad Laboratories Class A worth $6.75K as of Q2 2026.
- Brown Brothers Harriman & Co left its Bio-Rad Laboratories Class A share count unchanged in Q2 2026.
- Bio-Rad Laboratories Class A made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1496 holding.
- Brown Brothers Harriman & Co first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 44 quarters since.
- Brown Brothers Harriman & Co's Bio-Rad Laboratories Class A position peaked at $69M in Q2 2013.
- 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.